Sutro Biopharma (STRO) to Release Quarterly Earnings on Thursday

Sutro Biopharma (NASDAQ:STRO) is expected to issue its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($4.66) per share and revenue of $9.2630 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

Sutro Biopharma Price Performance

Shares of NASDAQ:STRO opened at $21.31 on Thursday. Sutro Biopharma has a 12 month low of $5.23 and a 12 month high of $21.42. The stock has a market cap of $181.35 million, a price-to-earnings ratio of -0.82 and a beta of 1.47. The stock’s 50 day moving average price is $15.07 and its 200 day moving average price is $11.27.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bridgeway Capital Management LLC grew its stake in shares of Sutro Biopharma by 232.6% during the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $37,000 after purchasing an additional 30,000 shares during the last quarter. Invesco Ltd. raised its position in shares of Sutro Biopharma by 137.8% during the first quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock worth $60,000 after acquiring an additional 53,390 shares during the last quarter. Cerity Partners LLC lifted its stake in shares of Sutro Biopharma by 169.9% during the second quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock valued at $75,000 after acquiring an additional 66,372 shares during the period. Qube Research & Technologies Ltd bought a new position in Sutro Biopharma in the second quarter valued at about $82,000. Finally, State of Tennessee Department of Treasury acquired a new stake in Sutro Biopharma in the fourth quarter worth about $86,000. Institutional investors own 96.99% of the company’s stock.

Analyst Ratings Changes

STRO has been the topic of a number of research reports. Wall Street Zen lowered Sutro Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Wedbush reaffirmed a “neutral” rating and set a $100.00 price objective (up from $20.00) on shares of Sutro Biopharma in a research report on Tuesday, December 2nd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sutro Biopharma in a research report on Wednesday, December 17th. Citigroup upgraded shares of Sutro Biopharma to an “outperform” rating in a report on Tuesday, January 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Monday, December 22nd. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $31.83.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.